H. Heuer

894 total citations
43 papers, 725 citations indexed

About

H. Heuer is a scholar working on Physiology, Cardiology and Cardiovascular Medicine and Pulmonary and Respiratory Medicine. According to data from OpenAlex, H. Heuer has authored 43 papers receiving a total of 725 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Physiology, 7 papers in Cardiology and Cardiovascular Medicine and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in H. Heuer's work include Asthma and respiratory diseases (13 papers), Antiplatelet Therapy and Cardiovascular Diseases (7 papers) and Neuropeptides and Animal Physiology (5 papers). H. Heuer is often cited by papers focused on Asthma and respiratory diseases (13 papers), Antiplatelet Therapy and Cardiovascular Diseases (7 papers) and Neuropeptides and Animal Physiology (5 papers). H. Heuer collaborates with scholars based in Germany, Egypt and United States. H. Heuer's co-authors include J. Casals‐Stenzel, Christopher J. Meade, K. H. Weber, G. Muačević, Karl Weber, Werner Kramer, Frank Girbig, Daniel Corsiero, H. M. Brecht and Wendelin Frick and has published in prestigious journals such as FEBS Letters, Hypertension and Methods in enzymology on CD-ROM/Methods in enzymology.

In The Last Decade

H. Heuer

43 papers receiving 687 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
H. Heuer Germany 15 224 158 150 137 103 43 725
L. Selmeci Hungary 14 174 0.8× 84 0.5× 123 0.8× 84 0.6× 90 0.9× 51 705
Fuu‐Jen Tsai Taiwan 16 295 1.3× 103 0.7× 86 0.6× 83 0.6× 82 0.8× 52 693
J. Oiknine Israel 11 179 0.8× 90 0.6× 218 1.5× 49 0.4× 130 1.3× 12 737
D. L. Widomski United States 17 194 0.9× 160 1.0× 78 0.5× 103 0.8× 214 2.1× 44 758
Karine Egan United States 10 209 0.9× 138 0.9× 101 0.7× 50 0.4× 140 1.4× 13 897
K. Rühling Germany 10 151 0.7× 134 0.8× 147 1.0× 39 0.3× 176 1.7× 20 629
C. M. Mansbach United States 18 305 1.4× 216 1.4× 258 1.7× 131 1.0× 42 0.4× 32 971
Richard Jaszewski United States 19 331 1.5× 108 0.7× 357 2.4× 225 1.6× 57 0.6× 40 1.1k
Hiromitsu Yokota Japan 20 579 2.6× 163 1.0× 129 0.9× 114 0.8× 114 1.1× 60 1.1k
Sayaka Arakawa Japan 11 183 0.8× 218 1.4× 70 0.5× 70 0.5× 96 0.9× 36 731

Countries citing papers authored by H. Heuer

Since Specialization
Citations

This map shows the geographic impact of H. Heuer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by H. Heuer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites H. Heuer more than expected).

Fields of papers citing papers by H. Heuer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by H. Heuer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by H. Heuer. The network helps show where H. Heuer may publish in the future.

Co-authorship network of co-authors of H. Heuer

This figure shows the co-authorship network connecting the top 25 collaborators of H. Heuer. A scholar is included among the top collaborators of H. Heuer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with H. Heuer. H. Heuer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Bickel, Martin, Wendelin Frick, Heiner Glombik, et al.. (2011). Effects of AVE2268, a Substituted Glycopyranoside, on Urinary Glucose Excretion and Blood Glucose in Mice and Rats. Arzneimittelforschung. 58(11). 574–580. 18 indexed citations
2.
Frick, Wendelin, Jochen Bauer, Frank Girbig, et al.. (2003). Synthesis of a biotin-tagged photoaffinity probe of 2-azetidinone cholesterol absorption inhibitors. Bioorganic & Medicinal Chemistry. 11(8). 1639–1642. 21 indexed citations
3.
Kramer, Werner, et al.. (2000). Identification of binding proteins for cholesterol absorption inhibitors as components of the intestinal cholesterol transporter. FEBS Letters. 487(2). 293–297. 47 indexed citations
4.
5.
Heuer, H., et al.. (1996). Characterisation of a novel airway late phase model in the sensitized guinea pig which uses silica and Bordetella pertussis as adjuvant for sensitization. European Journal of Pharmacology. 317(2-3). 361–368. 3 indexed citations
6.
7.
Heuer, H., et al.. (1994). Dissociation of airway responsiveness and bronchoalveolar lavage (BAL) cell composition in sensitized guinea–pigs after daily inhalation of ovalbumin. Clinical & Experimental Allergy. 24(7). 682–689. 15 indexed citations
8.
Gundel, Robert H., Craig D. Wegner, H. Heuer, & L. Gordon Letts. (1992). A PAF receptor antagonist inhibits acute airway inflammation and late‐phase responses but not chronic airway inflammation and hyperresponsiveness in a primate model of asthma. Mediators of Inflammation. 1(6). 379–384. 3 indexed citations
9.
Heuer, H.. (1992). Current status of PAF antagonists. Clinical & Experimental Allergy. 22(11). 980–983. 13 indexed citations
10.
Gundel, Robert H., H. Heuer, & L. Gordon Letts. (1992). Is platelet activating factor (PAF) an important mediator in bronchial asthma?. Mediators of Inflammation. 1(6). 367–369. 1 indexed citations
11.
Heuer, H.. (1991). Inhibition of active anaphylaxis in mice and guinea pigs by the new hetrazepinoic PAF antagonist bepafant (WEB 2170). European Journal of Pharmacology. 199(2). 157–163. 8 indexed citations
12.
Meade, Christopher J. & H. Heuer. (1991). PAF Antagonism as an Approach to the Treatment of Airway Hyperreactivity. American Review of Respiratory Disease. 143(3_pt_2). S79–S82. 6 indexed citations
13.
Heuer, H., Boris von Keller, & Klaus Urich. (1991). Action of the racemate and the isomers of the platelet-activating factor antagonist bepafant (WEB 2170) after oral administration to guinea-pigs and rats. Naunyn-Schmiedeberg s Archives of Pharmacology. 343(5). 546–50. 6 indexed citations
14.
Meade, Christopher J., et al.. (1991). Biochemical pharmacology of platelet-activating factor (and paf antagonists) in relation to clinical and experimental thrombocytopenia. Biochemical Pharmacology. 41(5). 657–668. 18 indexed citations
15.
Heuer, H., et al.. (1990). Inhibitory effects of the new PAF acether antagonist WEB-2086 on pharmacologic changes induced by PAF inhalation in human beings. Clinical Pharmacology & Therapeutics. 47(4). 456–462. 43 indexed citations
16.
Heuer, H., J. Casals‐Stenzel, G. Muačević, & K. H. Weber. (1990). Pharmacologic activity of bepafant (WEB 2170), a new and selective hetrazepinoic antagonist of platelet activating factor.. Journal of Pharmacology and Experimental Therapeutics. 255(3). 962–968. 95 indexed citations
17.
Weber, Karl & H. Heuer. (1989). Hetrazepines as antagonists of platelet activating factor. Medicinal Research Reviews. 9(2). 181–218. 31 indexed citations
18.
Heuer, H., et al.. (1989). Safety, tolerability., and pharmacologic activity of multiple doses of the new platelet activating factor antagonist WEB 2086 in human subjects. Clinical Pharmacology & Therapeutics. 45(3). 270–276. 24 indexed citations
19.
Heuer, H. & J. Casals‐Stenzel. (1989). The pathophysiological role of PAF in anaphylactic lung reaction in the guinea pig and in endotoxin shock evidenced by the specific PAF-antagonist WEB 2086.. PubMed. 308. 925–30. 3 indexed citations
20.
Heuer, H. & J. Casals‐Stenzel. (1988). Effect of the PAF-Antagonist Web 2086 on Anaphylactic Lung Beaction: Comparison of Inhalative and Intravenous Challenge. Birkhäuser Basel eBooks. 23. 207–215. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by L. Selmeci Breakdown of academic impact, for papers by Fuu‐Jen Tsai Breakdown of academic impact, for papers by J. Oiknine Breakdown of academic impact, for papers by D. L. Widomski Breakdown of academic impact, for papers by Karine Egan Breakdown of academic impact, for papers by K. Rühling Breakdown of academic impact, for papers by C. M. Mansbach Breakdown of academic impact, for papers by Richard Jaszewski Breakdown of academic impact, for papers by Hiromitsu Yokota Breakdown of academic impact, for papers by Sayaka Arakawa
Rankless by CCL
2026